Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ATUM
Newark, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
ATUM provides gene synthesis, protein engineering, antibody development, and cell line solutions for biopharmaceutical R&D; it is not a therapeutic pipeline company, so it does not publish clinical results.
- Modalities
- Monoclonal antibodyAntibodyAntibody fragmentProteinRecombinant proteinEnzyme replacement therapyCell lineGene therapySmall molecule
- Industry
- Drug Discovery Services
02
Partnerships
AldevronUniversity of Pennsylvania Gene Therapy ProgramNewcastle UniversityVTU TechnologySt. George’s University of LondonJust BiotherapeuticsSolentimPhylex BioSciencesTrioBioAnagram Therapeutics
Beyond the preview
Go deeper on ATUM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATUM.